Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to find out what effects taking the drug bevacizumab
together with two chemotherapeutic agents, docetaxel and cyclophosphamide followed by
doxorubicin alone before surgery will on breast cancer. Bevacizumab will be given for twelve
weeks in combination with chemotherapy then it ill be held during the administration of
doxorubicin. Twenty-eight to fifty-six days after undergoing surgery, all patients will
receive nine three-weekly infusions of bevacizumab.